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Summary 
The acute effects of β-adrenergic stimulation on myocardial 
stiffness were evaluated. New-Zealand white rabbits were treated 
with saline (control group) or doxorubicin to induce heart failure 
(HF) (DOXO-HF group). Effects of isoprenaline (10-10-10-5 M), a 
non-selective β-adrenergic agonist, were tested in papillary 
muscles from both groups. In the control group, the effects of 
isoprenaline were also evaluated in the presence of a damaged 
endocardial endothelium, atenolol (β1-adrenoceptor antagonist), 
ICI-118551 (β2-adrenoceptor antagonist), KT-5720 (PKA 
inhibitor), L-NNA (NO-synthase inhibitor), or indomethacin 
(cyclooxygenase inhibitor). Passive length-tension relations were 
constructed before and after adding isoprenaline (10-5 M). In the 
control group, isoprenaline increased resting muscle length up to 
1.017±0.006 L/Lmax. Correction of resting muscle length to its 
initial value resulted in a 28.5±3.1 % decrease of resting tension, 
indicating decreased muscle stiffness, as confirmed by the 
isoprenaline-induced right-downward shift of the passive length-
tension relation. These effects were modulated by β1- and β2-
adrenoceptors and PKA. In DOXO-HF group, the effect on 
myocardial stiffness was significantly decreased. We conclude 
that β-adrenergic stimulation is a relevant mechanism of acute 
neurohumoral modulation of the diastolic function. Furthermore, 
this study clarifies the mechanisms by which myocardial stiffness 
is decreased. 
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Introduction 
 
Although the evaluation of the myocardial 
function of the heart is usually focused on its 
chronotropic and inotropic state, the assessment of the 
diastolic response to pharmacological intervention is 
presently recognized as one of great clinical relevance. 
The most important mechanisms that increase resistance 
to left ventricular (LV) filling and consequently, lead to 
diastolic dysfunction and diastolic heart failure (HF), are 
impaired cardiac relaxation and increased stiffness (Leite-
Moreira 2006). 
Beta-adrenergic stimulation is an important 
physiological mechanism for enhancing cardiac 
performance during increased circulatory demands. The 
activation of these receptors on cardiac myocytes initiates 
signalling pathways that increase contractility and 
accelerate relaxation. Nowadays, three β-adrenoceptor 
subtypes have been identified, β1-, β2-, and β3-
adrenoceptor. Mammalian cardiac myocytes express 
predominantly β1-adrenoceptor, in a range from 60-80 % 
depending on the species, and in a less extent  
β2-adrenoceptor. These receptors modulate systolic and 
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diastolic functions in very different ways (for review see 
Brodde et al. 2006). The effects of β-adrenergic 
stimulation are partially mediated by cAMP-dependent 
protein kinase A (PKA) that subsequently phosphorylates 
several intracellular substrates, including membrane 
channels and myofilamentary proteins such as actin and 
myosin. Fast changes in intracellular Ca2+-handling are 
thought to be largely responsible for the positive inotropy 
and lusitropy. Some of the mechanisms underlying Ca2+ 
homeostasis and responsible for increasing lusitropy are 
the phosphorylation of: 1) phospholamban, enhancing 
Ca2+ reuptake into the sarcoplasmatic reticulum (Bers and 
Guo 2005), 2) troponin I (TnI), decreasing myocardial 
calcium (Ca2+) sensitivity on the thin filaments by 
increasing the rate at which Ca2+ dissociates from 
troponin C (TnC) (Robertson et al. 1982, 
Wattanapermpool et al. 1995, Zhang et al. 1995, Johns et 
al. 1997, Fentzke et al. 1999) and 3) myosin binding 
protein-C (MyBP-C), accelerating crossbridge cycling 
and increasing myofibrillar ATPase activity (Gruen et al. 
1999, Kunst et al. 2000). These mechanisms, which can 
be modulated by β-adrenergic stimulation, may lead to a 
faster rate of myofibrillar relaxation thereby shortening 
twitch duration. 
Besides relaxation, myocardial stiffness is a 
major determinant of diastolic function (Leite-Moreira 
2006). We previously demonstrated acute changes of 
myocardial stiffness after myocardial exposure to several 
neurohumoral agents like endothelin-1 (Leite-Moreira et 
al. 2003), angiotensin II (Leite-Moreira et al. 2006), 
urotensin II (Fontes-Sousa et al. 2007) and 
adrenomedullin (Fontes-Sousa et al. 2009). In the same 
way, nitric oxide (NO) decreases myocardial stiffness 
(Paulus et al. 1994, Shah and MacCarthy 2000). 
Furthermore, diastolic dysfunction induced by excessive 
afterload was attenuated by β-adrenergic stimulation, 
highlighting the lusitropic effects of this neurohumoral 
system (Leite-Moreira et al. 2001). However, the 
underlying mechanisms remain unexplored. 
In this context, the present study aims at 
exploring the effects of β-adrenergic stimulation on 
myocardial passive properties, investigating: 1) the 
effects on myocardial stiffness in healthy rabbits and its 
underlying mechanisms, and 2) whether this effect is 
preserved in an animal model of HF. 
 
Methods 
 
This study was performed in New-Zealand 
White rabbits (Oryctolagus cuniculus) and complied with 
the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
Publication Nº 85-23, Revised 1996). 
 
Heart Failure Model 
A well-documented regimen was used for the 
induction of HF secondary to doxorubicin toxicity 
(Arnolda et al. 1985). Adult male New Zealand White 
rabbits received doxorubicin (DOXO-HF) via a marginal 
ear vein by bolus injection (1 mg/kg) twice a week during 
8 weeks (n=9) followed by a washout period of one 
week. This model culminates with a depressed 
myocardial function compatible with dilated 
cardiomyopathy, as we previously demonstrated by 
echocardiography (Bras-Silva et al. 2006). Control 
rabbits (n=39) received vehicle (0.9 % saline) in 
equivolumetric doses during the same period. 
 
Experimental preparation 
Isometric and isotonic contractions were 
analyzed in papillary muscles isolated from the right 
ventricle of control (n=73) and DOXO-HF (n=9) rabbits, 
one week after the last administration of doxorubicin or 
saline. Male rabbits (2.3±0.1 kg, n=48) were anesthetized 
with intravenous sodium pentobarbital (25 mg.kg-1).  
A left thoracotomy was performed, beating hearts were 
quickly excised and immersed in a modified Krebs-
Ringer solution at 35 ºC, with 5 % Newborn Calf Serum 
and with cardioplegic 2,3-butanedione monoxime (BDM, 
3 %), a selective inhibitor of cross-bridge cycling to stop 
mechanical activity and preserve myocardial metabolism. 
The modified Krebs–Ringer solutions contained (in mM): 
98 NaCl, 4.7 KCl, 2.4 MgSO4.7H2O, 1.2 KH2PO4,  
4.5 glucose, 1.8 CaCl2.2H2O, 17 NaHCO3, 15 C3H3O3Na, 
5 CH3COONa and 0.003 prazosin). Prazosin, an  
α-adrenergic antagonist, was used to prevent α-adrenergic 
mediated effects. The solutions were in equilibrium with 
95 % O2 and 5 % CO2, to obtain a pH between 7.38-7.42. 
The right ventricle was opened and papillary 
muscles were isolated by first dividing the chordae 
tendinae at the muscle tip and then freeing the muscle 
base and a small amount of surrounding myocardium 
from the ventricular wall. The time from thoracotomy to 
dissection was ~3 min and only long, thin, uniformly 
cylindrical muscles were used. 
After dissection, papillary muscles (n=82, 
length: 3.8±0.1 mm, weight: 3.2±0.2 mg, preload: 
3.6±0.1 mN) were mounted vertically in a 10 ml plexi 
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glass organ bath containing the aforementioned Krebs-
Ringer solution. The lower muscular end was fixed in a 
phosphorbronze clip and the upper tendinous end was 
attached to an electromagnetic length-tension transducer 
(University of Antwerp, Belgium) (Brutsaert et al. 1971). 
Preload was initially set between 3 to 4 mN 
according to muscle dimensions. The preparations were 
stimulated at 0.6 Hz with a voltage of 10 % above 
threshold (typically 30-60 mV) by rectangular pulses of 
5 ms duration through two platinum electrodes arranged 
longitudinally alongside the entire muscle. After 20 min, 
bathing solutions were replaced by corresponding Krebs-
Ringer solutions without BDM and the muscle started to 
contract. One hour later, bathing solution was replaced by 
corresponding serum-free Krebs-Ringer solution. During 
the next 2 hours the muscles stabilized. Finally, the 
muscles were stretched to a muscle length at which active 
force development was maximal (Lmax). During the 
experiment, changes in diastolic muscle length and 
muscle shortening were measured by the isotonic 
transducer. Protocols were initiated after obtaining two 
similar isotonic and isometric control twitches separated 
by a 10 min interval. Throughout the entire experiment, 
the temperature was set at 35 ºC. 
At the end of the experiment the muscles were 
removed, lightly blotted and then weighed. Muscle cross-
sectional area was calculated by dividing the weight of 
the muscle by its length at Lmax. A cylindrical shape and a 
specific density of 1.0 were assumed. Muscle tension was 
then expressed as force normalized per cross-sectional 
area (mN/mm2). 
 
Experimental protocols 
Effects of increasing concentrations of 
isoprenaline (ISO, 10-10 to 10-5 M), a non-selective  
β-adrenergic agonist, were studied in papillary muscles 
from the control (n=13) and DOXO-HF (n=9) groups. In 
another set of papillary muscles from the control group, 
myocardial effects of increasing concentrations of 
isoprenaline (10-10 to 10-5 M) were evaluated in the 
presence of (i) atenolol (selective β1-adrenoceptor 
antagonist, 2*10-5 M, n=8), (ii) ICI 118,551 
hydrochloride (ICI, selective β2-adrenoceptor antagonist, 
10-6 M, n=8) or (iii) KT-5720 (KT, inhibitor of protein 
kinase A (PKA), 10-6 M, n=6). Considering that the 
modulation of myocardial stiffness by other 
neurohumoral agents require an intact endocardial 
endothelium (EE) (Bras-Silva and Leite-Moreira 2006) 
and that DOXO-HF model presents functional evidences 
of EE dysfunction (Bras-Silva et al. 2006), the same 
range of isoprenaline concentrations were studied in 
papillary muscles from control rabbits after (iv) damaging 
the EE (TRX, n=12) or in the presence of (v) NG-nitro-L-
arginine (L-NNA, nitric oxide synthase inhibitor, 10-5 M, 
n=7) or (vi) indomethacin (INDO, cyclooxygenase 
inhibitor, 10-5 M, n=7), two important EE mediators. EE 
was damaged by briefly (1 s) exposing the isolated 
papillary muscle to a weak solution (0.5 %) of the 
detergent Triton X-100 (Brutsaert et al. 1988, Leite-
Moreira and Bras-Silva 2004). 
The concentrations of atenolol, ICI 118,551, KT, 
NG-nitro-L-arginine and indomethacin were selected on 
the basis of several studies showing that their 
physiological effects on myocardial tissue or whole heart 
preparations are exerted by concentrations in the 
micromolar range (Mohan et al. 1995, Haikala et al. 
1997, Varma et al. 1999, Bras-Silva et al. 2008, Faucher 
et al. 2008). 
Most of the substances were dissolved in a 
Krebs-Ringer solution bath before the addition of 
isoprenaline, except for atenolol, which was added to the 
initial Krebs-Ringer solution at the final concentration. 
Muscle twitches were recorded after a stable response 
was obtained, typically 20 minutes following addition of 
the antagonists/inhibitors to the muscle preparation. After 
that, isoprenaline was added cumulatively without any 
washout in between, with a maximal effect occurring 
approximately 3-5 min after the latest addition. 
In a last set of papillary muscles from control 
rabbits, passive length-tension relations were constructed 
before and after a single concentration of isoprenaline 
(10-5 M, n=6). It consisted in decreasing the passive 
tension of the muscle in a stepwise manner (10 %), with 
an interval between each reduction of ~4 min until 
reaching 40 % of its initial passive tension. After 
restoring passive tension to its initial value, isoprenaline 
was added to the bath. Five minutes later, another passive 
tension reduction protocol was performed. 
Since all the experiments were performed in the 
presence of prazosin (3 μM), as described above, we 
evaluated its effects on myocardial function in papillary 
muscles from control animals (n=6, included in the total 
number given above). Prazosin did not change 
myocardial performance (data not shown). 
Papillary muscles obtained from the same rabbit 
were used for different experimental protocols. All 
chemicals were obtained from Sigma Chemical Co, St 
Louis, Mo, except ICI 118,551 hydrochloride that was 
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obtained from Tocris Bioscience, Missouri, USA.  
Most of the stock solutions, including 
isoprenaline, were prepared in distilled water and stored 
as frozen aliquots at –20 ºC until use. KT ester was 
dissolved in DMSO (less than 0.1 % in the bath) and 
water. No statistically significant differences were 
observed between control experiments, made in the 
absence or in the presence of the solvent at the maximal 
concentrations used (0.5 %, v/v). The pH of the 
superfusion solution did not change following addition of 
the drugs to the muscle preparations. 
 
Data analysis 
Isotonic and isometric twitches were converted 
online to digital data with a sampling frequency of 1000 
Hz (Daqbook/120, IOTech Inc. Cleveland, Ohio, USA) 
and analyzed with specific software (University of 
Antwerp, Belgium). 
Selected parameters included: active tension 
(AT, mN/mm2), maximum velocities of tension rise 
(dT/dtmax, mN/mm2) and decline (dT/dtmin, mN/mm2/s1), 
peak isotonic shortening (PS, % Lmax), maximum 
velocities of shortening (dL/dtmax, Lmaxs-1) and 
lengthening (dL/dtmin, Lmaxs-1), time to half-relaxation 
(tHR, ms), and time to active tension (tAT, ms), resting 
tension (RT, mN/mm2), and muscle length (L, L/Lmax). 
In the various protocols, results are given as 
percent change from baseline. For the parameters that are 
expressed as negative values (e.g. dT/dtmin), such percent 
change refers to the absolute values. When a 
pharmacological inhibitor was used or the EE damaged, 
the term baseline refers to the experimental condition in 
presence of those inhibitors or after EE damaging, before 
the addition of isoprenaline. 
An exponential curve was fitted to passive 
length-tension relations either before or after isoprenaline 
administration (10-5 M) to calculate muscle stiffness 
constant (Kc). 
 
Statistical methods 
Values are means ± S.E.M and n represents the 
number of experiments. Statistical significance was 
determined using analysis of variances (ANOVA) and 
Student-Newman-Keuls for pairwise multiple 
comparisons. P<0.05 was accepted as significant. 
 
Results 
 
Mean values of the morphological and 
contractile parameters in papillary muscles from the 
control group (n=73) and from the DOXO-HF group 
(n=9) are shown in Table 1. Morphometric characteristics 
and baseline performance of rabbit papillary muscles 
from control group were similar within all the 
experimental protocols. Compared with control group, 
papillary muscles from DOXO-HF rabbits showed lower 
baseline performance, indicating contractile dysfunction. 
 
 
Table 1. Mean values of the morphologic and contractile 
parameters in papillary muscles from the control and 
doxorubicin-induced heart failure (DOXO-HF). 
 
Parameter Control 
group (n=73) 
DOXO-HF 
group (n=9) 
Length (mm) 3.9 ± 0.2 3.9 ± 0.2 
Weight (mg) 3.1 ± 0.2 4.2 ± 0.6* 
Preload (mN) 3.8 ± 0.1 2.8 ± 0.4 
AT (mN/mm2) 27.6 ± 2.0 7.2 ± 1.9* 
dT/dtmax (mN/mm2/s) 197.4 ± 14.5 61.6 ± 11.2* 
dT/dtmin (mN/mm2/s) - 149.2 ± 9.2 - 54.9 ± 9.2* 
tHR (ms) 382.9 ± 10.1 265.4 ± 28.6* 
tAT (ms) 239.1 ± 5.6 175.9 ± 17.8* 
PS (%Lmax) 12.9 ± 0.6 5.6 ± 0.7* 
dL/dtmax (Lmax/s) 1.0 ± 0.05 0.5 ± 0.1* 
dL/dtmin (Lmax/s) -3.7 ± 0.2 -1.3 ± 0.2* 
 
AT: active tension; dT/dtmax, dT/dtmin: maximum velocities of 
tension rise and decline, respectively; tHR: time to half 
relaxation; tAT: time to active tension; PS: peak isotonic 
shortening; dL/dtmax, dL/dtmin: maximum velocities of shortening 
and lengthening, respectively. Values are means ± S.E.M.  
P< 0.05: * vs control group baseline values. 
 
 
Effects of increasing concentration of 
isoprenaline on the systolic and diastolic properties of 
isolated papillary muscles are illustrated in Figures 1 and 
2. In the control group with intact EE, increasing 
concentrations of isoprenaline enhanced both contractility 
(AT and dT/dtmax) and lusitropy (dT/dtmin, tAT and tHR). 
The highest concentration of isoprenaline (10-5 M) 
increased AT by 107.4±7.9 %, dT/dtmax by 276.2±27.6 % 
and dT/dtmin by 182.1±16.1 % (p<0.05, Fig. 1a). On the 
contrary, tAT and tHR decreased by 36.8±3.5 % and 
33.0±3.2 %, respectively (p<0.05, Fig. 1b). Concerning 
the diastolic properties of the myocardium, besides 
increasing relaxation rate (dT/dtmin), decreasing time to 
half relaxation (tHR) and promoting an earlier onset of 
relaxation (tAT), isoprenaline progressively increased 
resting muscle length, at a constant resting tension, up to 
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1.017±0.006 L/Lmax (Fig. 2). Correcting final muscle 
length to its initial value resulted in a 28.5±3.1 % 
decrease of RT, without altering other contractile 
parameters. All these results indicate a decrease in muscle 
stiffness or, in other words, an increase in muscle 
distensibility. 
This aspect is further explored in Figure 3 where 
passive length-tension relations at baseline and in the 
presence of isoprenaline (10-5 M) are presented. Muscle 
stiffness constant (Kc) acutely decreased from 23.1±4.1 to 
20.9±4.0 mN/mm2 (p=0.048) while no significant 
changes were observed in the intercept of the stiffness 
curve (baseline: 4.6*10-10±1.7*10-9 mN/mm2, ISO: 
3.1*10-9±2.3*10-9 mN/mm2, p=0.44). 
As referred previously, the effects of 
isoprenaline were also tested in the presence of 
antagonists/inhibitors, and none of them modified per se 
baseline muscle performance. Selective antagonism of  
β1-adrenoceptor rightward shifted the concentration-
response curve of isoprenaline concerning its positive 
inotropic (AT) and lusitropic (dT/dtmin) effects. On the 
other hand, neither antagonism of β2-adrenoceptor nor 
PKA inhibition altered these effects (data not shown). 
Regarding the diastolic properties of the myocardium, 
interestingly, antagonism of β1-adrenoceptor and PKA 
inhibition significantly decreased isoprenaline effects on 
muscle length (L/Lmax, Fig. 4a). β2-adrenoceptor 
antagonism abolished this effect as no difference in 
L/Lmax was observed before and after adding the maximal 
concentration of isoprenaline (Fig. 4a). These findings 
together with the distinct EC50 values for positive 
inotropism (0.14±0.09 μM, Figure 1a) and decreased 
stiffness (879±6 μM, Fig. 2b) of isoprenaline highlight 
the dissociation between its effects on myocardial 
contractility and stiffness. 
In DOXO-HF group, increasing concentrations 
of isoprenaline promoted higher percentage of variation 
mostly because the baseline muscle performance was 
significantly lower (Table 1). Maximal concentration of 
isoprenaline increased AT by 380.2±83.4 %, dT/dtmax by 
513.6±95.2 %, dT/dtmin by 558.9±124.0 % and decreased 
tAT by 23.8±4.0 % and tHR by 24.4±3.8 % (p<0.05). 
Furthermore, isoprenaline-induced increase of 
distensibility was attenuated in DOXO-HF group 
(1.004±0.002 L/Lmax, Fig. 4b). 
In the control group, we additionally 
investigated the contribution of EE and its mediators on 
the increase of distensibility induced by isoprenaline. 
Neither its removal, nor the inhibition of prostaglandins 
(INDO) nor NO (L-NNA) release significantly altered the 
inotropic or lusitropic response to isoprenaline (TRX: 
increased AT by 209.4±54.8 %, dT/dtmax by 458.2± 
98.8 %, dT/dtmin by 268.1±51.8 % and decreased tAT by 
36.0±2.9 %, and tHR by 30.4±2.4 %, INDO: increased 
AT by 108.9±16.0 %, dT/dtmax by 238.7±31.9 %, dT/dtmin 
by 172.5±18.4 % and decreased tAT by 32.7±3.2 %, and 
tHR by 30.5±3.0 %, L-NNA: increased AT by 
137.6±66.4 %, dT/dtmax by 335.3±99.8 %, dT/dtmin by 
251.2±109.6 % and decreased tAT by 46.6±4.6 %, and 
tHR by 44.8±4.4 %). Additionally, none of these 
interventions significantly altered the effects of 
isoprenaline on muscle distensibility (Fig. 4c). 
The response of passive muscle length and 
tension to the maximal concentration of isoprenaline  
(10-5 M) alone and in all experimental protocols is 
summarised in Figure 5. Only the selective antagonism of 
β1-adrenoceptor, β2-adrenoceptor or the inhibition of 
 
Fig. 1. Effects of increasing concentrations of isoprenaline (ISO,
10-10 to 10-5 M; n=13) on: (a) active tension (AT), maximum
velocities of tension rise (dT/dtmax) and decline (dT/dtmin); and (b) 
time to half-relaxation (tHR) and time to active tension (tAT).
Data are means ± S.E.M. P<0.05: α vs baseline, β vs 10-10 M ISO, 
γ vs 10-9 M ISO, δ vs 10-8 M ISO, ε vs 10-7 M ISO. 
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PKA markedly reduced the effect of isoprenaline on 
muscle length, leading to a decrease in passive tension. 
The acute effect of β-adrenergic stimulation on muscle 
length in DOXO-HF animals was significantly decreased 
when compared with control group. 
 
Discussion 
 
The myocardial effects of β-adrenoceptor 
stimulation by isoprenaline on papillary muscles from 
healthy and DOXO-HF rabbits were evaluated in this 
study. Besides the demonstration of the well-documented 
positive inotropic and lusitropic effects (Bers 2002), the 
novel finding herein reported was that β-adrenergic 
stimulation induces a significant concentration-dependent 
acute decrease of myocardial stiffness, dependent on the 
activation of β1, β2-adrenoceptor and PKA. Both the 
endothelium and the evaluated endothelial mediators, NO 
and prostaglandins, did not interfere with this effect. 
Furthermore, this effect was significantly decreased in the 
presence of HF induced by doxorubicin. 
Myocardial function was evaluated in vitro using 
papillary muscles. This model has the advantage of 
excluding confounding systemic variables, such as 
changes in preload, afterload or coronary flow. 
Specifically in this study, the use of a rabbit model 
presents many advantages as both β1 and  
β2-adrenoceptors are present in its ventricular myocytes 
(Marian 2006), and the failing rabbit heart exhibits 
molecular changes in β-adrenergic signaling similar to 
those observed in human HF (Maurice et al. 1999). These 
characteristics make such species a suitable experimental 
model to study myocardial passive properties and 
performance under β-adrenergic stimulation. 
Beta-adrenergic stimulation induced by the 
sympathetic nervous system plays a pivotal role in the 
regulation of myocardial structure and function in the 
normal and failing heart. Several studies focusing on the 
effects of β-adrenergic stimulation support that 
crossbridge cycle and several other phosphorylation 
events are the major determinants of the intrinsic rate of 
myocardial relaxation (Bronzwaer and Paulus 2005). On 
the other hand, cardiac hypertrophy and failure are also 
characterized by an overall loss of sensitivity to  
β-adrenoceptor stimulation (Bristow et al. 1986, 
Steinberg 1999). However, the effects of β-adrenergic 
stimulation on other major determinants of diastolic 
function, such as the passive properties, like myocardial 
stiffness, remained to be clarified in both conditions. 
We observed that β-adrenoceptor stimulation 
decreases myocardial stiffness through both β1 and β2-AR 
activation. There has been a tendency to think of β1- and 
β2-adrenoceptors as being nearly equivalent, at least in 
terms of their cAMP-mediated effects, but there are 
important differences. Several studies focusing on the 
myocardial response to β2-adrenoceptor stimulation have 
reported that while there are similar agonist-dependent 
increases in tension development, the acceleration of 
relaxation typically seen with β1-adrenoceptor stimulation 
is attenuated or absent with β2-AR stimulation (Xiao et 
al. 1995). Although our results demonstrate a potential 
cardiovascular role for β2-AR as an acute modulator of 
myocardial stiffness, we cannot exclude an additional 
effect of ICI-118551 on β1-AR. 
In the current study, by using KT, a PKA specific 
inhibitor (Bishopric et al. 1992, Haikala et al. 1997, Kiehn 
et al. 1998, Iwai-Kanai et al. 1999), we confirmed that 
isoprenaline-induced decrease of myocardial stiffness is 
dependent on the activation of PKA which is consonant 
with previously published data on the effects of PKA in 
engineered rat heart tissue (Zimmermann et al. 2002) and 
human cardiac cells (Borbely et al. 2005, van Heerebeek 
 
 
Fig. 2. (a) Representative time band of 
isotonic contractions of electrically paced 
papillary muscles contractions. Increasing 
concentrations of isoprenaline (ISO; 10-7-
10-5 M, black arrows) induce a positive 
inotropic response (illustrated by an 
increase in muscle shortening with a 
decrease in systolic length), together with 
an increase in myocardial distensibility, 
represented by resting muscle length 
(L/Lmax), illustrated by a raise in resting 
muscle length from baseline, gray dotted 
line); (b) Effects of increasing 
concentrations of ISO (10-10 to 10-5 M; 
n=13) on resting muscle length (L/Lmax). 
Data are means ± S.E.M. P< 0.05: α vs
baseline, β vs 10-10 M ISO, γ vs 10-9 M ISO, 
δ vs 10-8 M ISO, ε vs 10-7 M ISO. 
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et al. 2006). Although our main goal was to study the role 
of isoprenaline on diastolic properties, we did not observe 
an antagonist activity of KT against isoprenaline effects on 
inotropism and lusitropism, which is in line with previous 
studies (Gotoh 1995, Yatani et al. 1999). These studies 
suggested that β-adrenergic stimulation increases the peak 
L-type Ca2+ current via PKA-independent activation of 
Ca2+ channels (Yatani et al. 1999) or increases calcium 
leak from sarcoplasmatic reticulum via calcium/ 
calmodulin-dependent protein kinase (Curran et al. 2007). 
The effects of sustained β1-adrenoceptor stimulation 
(inotropy, cell growth and cell death) are indeed primarily 
due to this latter pathway, rather than PKA signalling (Zhu 
et al. 2003, Wang et al. 2004). So, under certain 
physiological and pathological circumstances, this 
signaling pathway becomes more relevant (Singh et al. 
2001, Xiao 2001). 
Myocardial stiffness is determined both by 
cardiomyocytes’ cytoskeleton and the extracellular matrix 
(Kass et al. 2004). Most of the elastic force of the 
cardiomyocytes is now thought to reside in the cytoskeletal 
protein, titin (Kruger and Linke 2009) which is known to 
be phosphorylated by PKA, PKG and PKC (Fukuda et al. 
2005, Hidalgo et al. 2009, Kruger et al. 2009). Changes in 
its isoform composition and phosphorylation status have 
been shown to alter diastolic function and myocardial 
passive properties (Nagueh et al. 2004, Borbely et al. 
2009). Based on this evidence, one of the possibilities that 
could explain our observations is that the acute decrease of 
stiffness induced by isoprenaline is associated with the 
modulation of titin’s phosphorylation status by PKA, as 
demonstrated in the present study by its inhibition by KT. 
The acute decrease of myocardial stiffness 
induced by isoprenaline was attenuated in DOX-treated 
rabbits, where β-adrenoceptor downregulation has been 
 
 
Fig. 4. Effects of increasing concentrations of isoprenaline (ISO, 
10-10 to 10-5 M; n=8) on passive muscle length (L/Lmax): (a) in the 
absence (control; n=13) or presence of: a β1-adrenoceptor 
antagonist (atenolol, 2.10-5 M; n=8); a β2-adrenoceptor 
antagonist (ICI, 10-6 M; n=8) or a PKA inhibitor (KT, 10-6 M; 
n=6); (b) in doxorubicin-induced heart failure group (DOXO-HF, 
n=9); (c) in the presence of: damaged endothelial endothelium 
(TRX; n=12); a NO synthase inhibitor, NG-Nitro-L-Arginine 
(L-NNA, 10-6 M; n=7) or a cyclooxygenase inhibitor, indomethacin 
(INDO, 10-6 M; n=7). Data are means ± S.E.M., expressed as 
percent variation from baseline. P< 0.05: α vs baseline, β vs 10-10 
M ISO, γ vs 10-9 M ISO, δ vs 10-8 M ISO, ε vs 10-7 M ISO and * vs
ISO alone. 
 
 
Fig. 3. Passive length-tension relations at baseline (Kc=23.1, 
Intercept=4.6*10-10) and in the presence of isoprenaline (ISO, 
10-5 M, n=6; Kc=20.9, Intercept=3.1*10-9). Data are means ±
S.E.M. P<0.05: α ISO vs baseline. 
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documented (Nagami et al. 1997, Kizaki et al. 2004). 
However, other factors can account for this effect such as 
a shift in titin isoform. In this regard, a compensatory 
shift from the stiff N2B to the compliant N2BA isoform 
was described in patients with higher LV end-diastolic 
wall stress induced by dilated cardiomyopathy (Nagueh et 
al. 2004). Moreover, a smaller PKA-induced RT decrease 
was reported when the compliant N2BA titin isoform is 
phosphorylated rather than the stiff N2B isoform (Fukuda 
et al. 2005). We and others demonstrated an increase in 
LV-end-diastolic pressure and dilated cardiomyopathy in 
DOXO-HF rabbits (Nagami et al. 1997, Bras-Silva et al. 
2007). Therefore, we could speculate that in DOX-treated 
rabbits a similar compensatory shift from N2B to the 
non-PKA sensitive N2BA isoform could have taken place 
during the course of HF progression explaining the 
attenuation of the isoprenaline-induced decrease of 
myocardial stiffness in dilated DOXO-HF hearts. Even 
though interesting, the confirmation of this aspect is 
beyond the scope of the present study and needs further 
investigation. 
Another study of our group provided functional 
evidence of EE dysfunction in the DOXO-HF model 
(Bras-Silva and Leite-Moreira 2006). With regard to 
diastolic function, we have recently shown, in the same 
animal species, that the decrease of myocardial stiffness 
induced by ET-1 (Bras-Silva and Leite-Moreira 2006, 
Bras-Silva et al. 2008), urotensin II (Fontes-Sousa et al. 
2007) and adrenomedullin (Fontes-Sousa et al. 2009) was 
dependent on EE and/or its mediators (NO and 
prostaglandins). Therefore, we performed other series of 
experimental protocols in order to confirm whether EE 
integrity is mandatory for isoprenaline-induced decrease 
on myocardial stiffness. In this set of studies, we found 
that although there was a clear trend towards a decrease 
of the isoprenaline-induced decrease of myocardial 
stiffness after removing the EE or upon inhibition of 
prostaglandins’ release or NO synthase, none of these 
interventions was able per se to modify this effect. 
 
Conclusions 
 
Besides the well-known effects of β-adrenergic 
stimulation on myocardial contractility, the present study 
reveals that it acutely lowers myocardial stiffness. This 
novel effect, which requires the activation of β1 and β2-
adrenoceptor and is mediated by PKA, broadens our 
knowledge with regard to the acute neurohumoral 
modulation of diastolic function. This effect is of 
potential high physiological relevance as it might acutely 
decrease passive myocardial tension by as much as 30 %, 
allowing an intact heart to reach higher filling volumes at 
almost one third lower filling pressures. As this effect is 
abolished in the failing heart it might contribute to 
diastolic dysfunction in heart failure and therefore 
constitute a potential target for therapy. In this regard, 
these results highlight another possible important effect 
of β-blocker therapy in the treatment of HF. 
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